September Pharmaceutical Events: Corporate Issues: Frequent Major Actions such as Investment and Acquisitions of Listed Companies

Looking back at September 2021, the pharmaceutical industry has continued to make major investments and acquisitions, involving companies such as Huadong Medicine, Jilin Aodong, Yiqiao Shenzhou, and Tailong Pharmaceutical
.
Huadong Medicine: Has not lost control of East China Ningbo management Huadong Medicine issued an announcement on the evening of September 30, stating that it has not lost control of East China Ningbo management and plans to enter the statutory liquidation stage after its business expires on December 31, 2021
.
East China Ningbo’s revenue and profits account for a relatively low proportion of listed companies, and its contribution to the company has gradually decreased, which does not constitute a significant impact on overall operations
.
The company also stated that through the liquidation of East China Ningbo, its existing fixed assets will have a certain value-added income, which is also conducive to the overall planning and unified management of the medical beauty business in the future
.
Based on the principle of being responsible to all shareholders and safeguarding the interests of all shareholders, the company will properly complete the follow-up liquidation work of East China Ningbo in accordance with the law
.
Wuzhong, Jiangsu: plans to acquire no less than 70% equity of Shanghai Vina, Jiangsu Wuzhong announced on the evening of September 28 that the company or its wholly-owned subsidiary intends to acquire no less than 70% of Shanghai Vina.
The two parties tentatively decide to Shanghai The consideration for the acquisition of 100% equity of Weina is about 700 million yuan
.
According to the data, Shanghai Vina's main business is the research and development, production and sales of cosmetics products, mainly Korean brands
.
Jiangsu Wuzhong stated that the acquisition will help accelerate the implementation of the medical aesthetics industry strategy and the large-scale operation layout, and expand the product pipeline of the medical aesthetics sector
.
At the same time, with the help of Shanghai Vina's sales network and channels, other medical aesthetics products of the company can be quickly introduced in the follow-up to accelerate the formation of a coordinated linkage, complementary advantages, and rapid development of the medical aesthetics industry layout
.
Plyco: plans to invest 660 million yuan in the production of inactivated veterinary vaccines and other projects.
On September 23, Plyco announced that Nanjing Plyco, a wholly-owned subsidiary, plans to be invested by its wholly-owned subsidiary to solve the bottleneck in production capacity.
RMB 100 million to build a production base of inactivated veterinary vaccines with an annual production capacity of 2 billion milliliters for the production of highly pathogenic avian influenza vaccine products
.
The subsidiary Huizhong Biology intends to upgrade the existing production lines in accordance with the new version of veterinary drug GMP requirements, and increase the production capacity and automation level of the existing production lines; at the same time, it will build a new production line for bacterial inactivated vaccines and some pet vaccine product lines, with an estimated total investment of 260 million yuan
.
The actual controller of Tailong Pharmaceuticals intends to change Tailong Pharmaceuticals issued a reminder announcement on the planned change of control rights and the resumption of trading of the company’s shares on the evening of September 22.
The controlling shareholder Zhengzhou Zhongsheng Industrial Group Co.
, Ltd.
intends to establish a limited A partnership enterprise, transferring its 82,441,200 shares of the company held by it (accounting for 14.
37% of the company's total share capital)
.
If the transfer is completed, the partnership will hold 14.
37% of the company's shares and become the controlling shareholder, and the actual controller of the company will be changed to the Management Committee of Zhengzhou High-tech Industrial Development Zone
.
Yiqiao Shenzhou: intends to settle in Taizhou Pharmaceutical High-tech Industrial Park.
On September 14, Yiqiao Shenzhou announced that the company intends to sign the "Entry Agreement" with the Taizhou Pharmaceutical High-tech Industrial Park Management Committee and establish it in Taizhou Pharmaceutical High-tech Industrial Park.
A wholly-owned subsidiary, with a registered capital of 30 million yuan and a total investment of 150 million yuan, is mainly engaged in the research and development, production and sales of biological reagents represented by culture media, proteins, and antibody diagnostic materials
.
The park is responsible for providing about 10,900 square meters of standard workshops for the new company to lease, and the new company enjoys lease and tax preferential policies
.
Jilin Aodong: The controlling shareholder intends to spend 150 million to 300 million yuan to increase the shareholding.
Jilin Aodong announced on the evening of September 13 that the company has recently received the "Notice of Share Increase Plan" from the controlling shareholder Jincheng Company
.
Jincheng plans to increase its holdings of the company's shares with its own funds or self-raised funds within six months, with a total amount of not less than 150 million yuan and not more than 300 million yuan
.
The planned price of the share increase will not exceed RMB 23.
00 per share
.